. The disorder affected girls, who initially seemed to develop normally, but began to lose their previously achieved abilities -in particular, hand use and speech -at 7-18 months of age (or sometimes later, as has subsequently been shown 3 ). Our aim in this Review is to describe the 50-year journey from the recognition of RTT to the present day, a journey that has included iterations of the diagnostic criteria and growing understanding of the clinical and biological variation of the disorder. We focus particularly on the discovery that RTT is caused by a mutation on the MECP2 gene, the burgeoning knowledge of its neurobiology, and ensuing pathways to clinical trials. We include a detailed review of the phenotype and observed relationships with genotype, and reflect on how knowledge of RTT has advanced rapidly, in part due to database infrastructure, international collaborations and strong advocacy groups.
Pivotal discoveries and advances
The original description of RTT by Hagberg and colleagues 2 (FIG. 1) was followed by an explosion of literature about the disorder, much of which was published as proceedings of early meetings held in Vienna and Baltimore.
An important outcome of the first Vienna symposium was the need for a set of clinical criteria to facilitate diagnosis (FIG. 1) , and a schema of clinical characteristics with eight inclusionary and four exclusionary criteria was published soon afterwards 4 . Over the past three decades, these criteria have undergone several iterations [5] [6] [7] . The international workshop held in Baltimore was co-sponsored by a newly formed parent organization, the International Rett Syndrome Association, and was attended by over 85 health-care professionals, along with 70 girls with RTT and their families. This workshop was the beginning of a close collaboration between parents and researchers, which has contributed greatly to the rapid advancement of knowledge in this condition. A case series that emerged as a consequence was seminal in informing the medical community about the Abstract | In the 50 years since Andreas Rett first described the syndrome that came to bear his name, and is now known to be caused by a mutation in the methyl-CpG-binding protein 2 (MECP2) gene, a compelling blend of astute clinical observations and clinical and laboratory research has substantially enhanced our understanding of this rare disorder. Here, we document the contributions of the early pioneers in Rett syndrome (RTT) research, and describe the evolution of knowledge in terms of diagnostic criteria, clinical variation, and the interplay with other Rett-related disorders. We provide a synthesis of what is known about the neurobiology of MeCP2, considering the lessons learned from both cell and animal models, and how they might inform future clinical trials. With a focus on the core criteria, we examine the relationships between genotype and clinical severity. We review current knowledge about the many comorbidities that occur in RTT, and how genotype may modify their presentation. We also acknowledge the important drivers that are accelerating this research programme, including the roles of research infrastructure, international collaboration and advocacy groups. Finally, we highlight the major milestones since 1966, and what they mean for the day-to-day lives of individuals with RTT and their families. , as was the description of 19 cases in the west of Scotland 9 . A staging system, which characterized the disease profile into four distinct phases, was developed from information relating to 29 Swedish cases 10 . On the basis of citation history, this system seems to have been widely adopted but, as yet, has not been formally validated in the light of the currently available genetic knowledge and longitudinal data.
The pivotal discoveries that followed on from the original clinical revelations are outlined in FIG. 1 , and their enormous significance will become clear as we follow the story of RTT -in the laboratory, in the clinic and across the world -over a further three decades.
Identifying the genetic cause of RTT
The relationship between the MECP2 gene and RTT was discovered in Huda Zoghbi's laboratory in 1999 (REF. 11) (FIG. 1) . This crucial milestone was reached as a consequence of preceding exclusion mapping studies, which had narrowed down the area of interest on chromosome Xq28 (REFS 12, 13) . The nuclear protein MeCP2 had hitherto been of interest largely in the field of epigenetics, and the finding that MeCP2 lay at the root of RTT resulted in a convergence of clinical, neuroscience and epigenetics researchers to begin to understand the disease process.
This momentous discovery had two immediate sequelae, the first being its impact on research. A second study from the Zoghbi laboratory identified a MECP2 mutation in just over three-quarters of screened patients with sporadic RTT, and in two of seven familial cases 14 . Severity was scored from previous clinical observations, and mutations were categorized as either truncating or missense. Although nonrandom X-inactivation also affected the phenotype, no overall genotype-phenotype relationships were identified at this stage 14 . However, this was just the first of numerous such investigations that were conducted across the globe in the ensuing years [15] [16] [17] [18] . One of the earliest papers identified MECP2 mutations in 80% of typical RTT cases 18 . These included eight recurrent missense and nonsense mutations, which are now known to account for almost two-thirds of the mutations seen in RTT 19, 20 (FIG. 2) .
The second consequence of Zoghbi's findings was the burgeoning availability of genetic testing, at least in European countries with equitable public funding systems, and for appropriately insured patients in the USA. Sadly, however, genetic testing remains inaccessible to patients in many countries. Techniques other than direct sequencing, such as multiplex ligation-dependent probe amplification (MLPA), which is necessary for the identification of large deletions of exon 3 and 4 (REFS 21, 22) , have also become available. Such developments would have major implications for the subsequent identification of these mutation types.
Neurobiology of MeCP2
RTT is not considered to be a degenerative brain condition, but patients with this syndrome exhibit reductions in gross brain volume, which are associated with the presence of abnormally small, densely packed neurons with reduced dendritic complexity and synapse density 23 . The discovery, in 1999, that genetic lesions in the MECP2 gene represent the underlying cause of RTT 11 dramatically intensified efforts to model the disorder biologically. 
Key points
• In the 50 years since its description by Andreas Rett, we have witnessed an explosion of knowledge about Rett syndrome (RTT) in relation to its genetic basis and clinical characteristics, and their interrelationships • Initially, the diagnosis of RTT was based solely on clinical criteria, but identification of its genetic cause has revolutionized this process, while presenting new challenges as we enter the era of next-generation sequencing • Mutations in the methyl-CpG-binding protein 2 (MECP2) gene were found to be causative of RTT, accounting for fundamentally altered neurobiological pathways, and providing the stimulus to identify pathways that can be manipulated therapeutically • The type of MECP2 mutation is associated with clinical severity, and influences many aspects of the phenotype, including functional abilities, onset of scoliosis, bone health, and sleep disturbances • Considerable progress has been made in understanding the natural history of RTT, leading to improvement in clinical management in selected areas, and changes in attitudes and allocation of health-care resources have increased life expectancy • The advancement in knowledge about RTT has been dependent on global efforts to study this disorder, including the establishment of database infrastructures, the input of advocacy groups, and the development of international collaborations 
C-terminal deletions
MeCP2 is essential for normal brain function. Much of the work on MeCP2 has relied on patient-derived cells [24] [25] [26] [27] [28] and genetically modified mice, including Mecp2-knockout lines 29, 30 (FIG. 1) , as well as a variety of conditional knockout lines in which the gene has been deleted from specific brain regions or brain cell types [30] [31] [32] [33] [34] [35] [36] [37] [38] , or at different stages of development 39 . This work has shown that loss of MeCP2 disrupts the given brain region or system from which it is deleted, and that localized disruption results in a subset of the commonly observed symptoms of RTT. Deletion from GABAergic circuits, which are ubiquitous across brain systems, produces a near-complete Mecp2-null phenotype, including motor and cognitive impairments 32 . By contrast, deletion from glutamatergic cells causes anxiety and tremor 40 . Interestingly, postnatal deletion of Mecp2, even within a mature nervous system, results in RTT-like phenotypes 41, 42 . In mouse models, activation of a previously silenced Mecp2 allele globally, or within GABAergic neurons, reverses many established RTT-like phenotypes, including locomotor and behavioural impairments, and promotes functional and structural plasticity within the brain [43] [44] [45] (FIG. 1) . These findings suggest that many of the features that characterize an RTT-like disorder in mice are amenable to reversal, but also indicates that RTT is not a straightforward neurodevelopmental disorder, and that MeCP2 has an essential and ongoing role in the mature nervous system. These observations have important implications when considering potential therapeutic interventions. An important caveat in interpreting the mouse data is that hemizygous (Mecp2 −/y ) null male mice are frequently used experimentally, owing to their more overt and rapidly apparent phenotypes. One should note, however, that heterozygous (Mecp2 +/− ) female mice are the most accurate genetic representation of the majority of patients with RTT, despite the fact that they develop overt phenotypes at a much later developmental time point than do humans.
MeCP2 is especially abundant in postmitotic neurons 46, 47 , but is also expressed at modest levels in non-neuronal cells in the brain 48, 49 and in other tissues throughout the body 50, 51 . Deletion of Mecp2 from glia in mice has relatively minor phenotypic consequences, but restoration of MeCP2 to astrocytes in an otherwise MeCP2-deficient nervous system results in partial amelioration of phenotypes, including normalization of breathing patterns, motor activities and anxiety levels 48 . As also indicated in primary culture experiments 52 , MeCP2 in glial cells might contribute to certain non-cell-autonomous functions, such as supporting normal dendritic morphology through the release of trophic factors within the nervous system. However, a lack of functional MeCP2 in neurons is generally considered to be the dominant driver of RTT 53 .
MeCP2 in non-neural cells.
The relative importance of MeCP2 in peripheral tissues is unclear. The consequences of global MeCP2 deficiency are observed in several peripheral systems, and they include fatty liver and metabolic disease 54 , lung lesions 55 , cardiac effects 56, 57 , and aberrant bone phenotypes 58, 59 . Selective deletion of Mecp2 in hepatocytes did not recapitulate the metabolic dysfunction (insulin resistance, glucose tolerance and altered circulating fatty acids) or overt neurological effects 54 seen in knockout mice, but did recapitulate the fatty liver seen in some Mecp2-null lines, possibly reflecting a phenotype with a genuine peripheral origin. Evidence has also been obtained for altered bone cell regulation in MeCP2-deficient osteocytes 60 , probably explaining the osteoporotic phenotypes described in RTT. By contrast, no changes have been observed in skeletal muscle following selective local Mecp2 deletion 61 . Overall, MeCP2 depletion studies have revealed that the majority of RTT-like behavioural, sensorimotor and autonomic phenotypes are associated with MeCP2 deficiency in the brain. However, some less extreme but still clinically significant aspects of the disorder may arise independently of defects in the nervous system 51 .
MECP2 mutations and protein function. The structure and function of MeCP2 protein have been reviewed in detail elsewhere 39, 62 . The two known protein isoforms of MeCP2, MeCP2_e1 and MeCP2_e2, differ only at the extreme N-terminus and, despite some evidence for isoform-specific functions 63 , the two forms are considered to be largely functionally equivalent 53, 64 , although MeCP2_e1 is the dominant brain isoform. MeCP2 was originally discovered as a result of a biochemical screen for factors that interact with DNA, in particular, with methylated cytosines (within the context of CpG sequences) 65 . MeCP2 is a nuclear protein that tracks DNA methylation by virtue of its methyl-CpG-binding domain (MBD) 66 . Emerging evidence suggests that the MBD of MeCP2 does not interact exclusively with CpG dinucleotides, but also has an affinity for methylated CpA 67 . The MBD is also reported to interact with 5-hydroxymethylcytosine-containing DNA 68, 69 , and these modified DNA sequence contexts might be of special importance in the brain 70 . The importance of the MBD is highlighted by the fact that pathogenic missense mutations in this region cause reduced binding to methyl ated DNA 71 . Regions distinct from the MBD, including AT-hooks 72 and a basic cluster 73 , have also been implicated in DNA binding. The functional importance of these regions remains to be fully established, but it is possible that, together with the MBD, they contribute to chromatin structure.
A presumed major function of MeCP2 is to regulate gene expression at either a local or a global level. DNA methylation is a modification that is linked to gene silencing, and a long-held view is that MeCP2 is important in transcriptional repression 74 . However, MeCP2 has also been linked to gene activation 75 . MeCP2 interacts with a wide range of proteins 39 , including the histone deacetylase co-repressor complexes SIN3A, NCOR (nuclear receptor co-repressor) and SMRT (also known as NCOR2) [76] [77] [78] [79] . The NCOR-SMRT interaction domain (NID) has been mapped within the wider transcriptional repression domain (TRD) of MeCP2, and a cluster of RTT-causing missense mutations, including the common Arg306Cys variant, have been shown to disrupt this interaction 71 (FIG. 2) . These findings have led to the idea of a bridge model, whereby MeCP2 functions as a tether between DNA and the NCOR-SMRT complex, and missense mutations at either end of the bridge will result in RTT 71 . Recent reports suggest that MeCP2-associated transcriptional regulation is preferentially targeted to long genes, which might be important in the downstream cellular pathologies 80, 81 . In addition to the repressor model of MeCP2 function, a number of alternative or overlapping functions have been ascribed, including direct roles in chromatin remodelling (compaction) 82 , gene activation 75 , regulation of alternative splicing 83, 84 , and microRNA (miRNA) processing 85 . In turn, MeCP2 function can be regulated by mi RNAs 86, 87 and activity-dependent phosphorylation 88, 89 . The relevance of this latter mechanism to RTT is unclear, as no RTT-causing point mutations have been reported within known MeCP2 phosphorylation sites. The level of MeCP2 within a given cell type is believed to be crucial for normal cellular homeostasis, and both loss of function and overexpression have neurological consequences 53, [90] [91] [92] . MECP2 duplication syndrome, the clinical manifestation of overexpression, is more commonly reported in males than in females 91, 93 , and its phenotype is gradually being delineated. When modelled in mice, MECP2 duplication syndrome, like RTT, has shown the potential for phenotypic reversal when MeCP2 levels are restored to normal 94 . Loss of MeCP2 alters the cellular levels of many gene products, but the effects at the individual gene level are typically small 75, 95 , and are likely to be cell-type-specific. The fact that a wide variety of genes are affected suggests that the existence of a single pathogenic pathway that can act as a focus for all therapeutic interventions is unlikely. Downstream, many cellular systems are disrupted, and there have been reports of altered synaptic function and plasticity 43, [96] [97] [98] [99] [100] , reduced protein synthesis 101 , impaired mitochondrial function 102 , oxidative stress 103 , and alterations in various signalling and homeostatic pathways, such as the mTOR-AKT pathway 101 and energy and lipid metabolism 54 . The relative importance of these effects to cellular dysfunction may depend on the type and state of the cell. 1) . The modifications included a slight expansion of the exclusion criteria, and the addition of a set of supportive criteria relating to breathing dysfunction, peripheral vasomotor disturbances, seizures, scoliosis, growth retardation and small feet.
Clinical features and diagnosis
The revised diagnostic criteria were initially restricted to include only classic cases of RTT
see Supplementary information S1 (video)), with the intention of providing a homogenous patient population
Box 1 | Severe Rett syndrome phenotype
The severe Rett syndrome (RTT) phenotype is exemplified by a 12-year-old girl with the Arg270X mutation in the methyl-CpG-binding protein 2 (MECP2) gene (see Supplementary information S1 (video)). She learned to sit at 9 months, but did not learn to walk. She did learn to say "mum", "dad" and "nan", but she found it difficult to grasp objects. Her mother was concerned about her poor developmental progress and jerky movements, and sought specialist advice when, at 14 months, her daughter suddenly stopped using words and developed hand stereotypies. RTT was confirmed at the age of 2 years by the presence of a MECP2 Arg270X mutation, an early diagnosis that was consistent with her severe clinical presentation (FIGS 2-5).
The girl exhibited early regression of communication skills but no apparent loss of hand function. As a young child, she could grasp a large object but could not hold it -a feature that she still demonstrates. She also illustrates many other features of RTT. Altered breathing patterns first developed at 18 months, and she still experiences daily hyperventilation and breath-holding with abdominal bloating. Epilepsy was diagnosed at the age of 4 years 8 months, although her seizures are currently well controlled. Since the age of 9 years, she has been fed via a gastrostomy tube to ensure adequate fluids and nutrition, and to protect her respiratory health. Scoliosis was diagnosed at 5 years, and she underwent spinal fusion at 9 years. She has also sustained several long bone fractures in the lower limbs.
The girl's sleep is regularly disturbed; she grinds her teeth, has a high pain tolerance and also has small and cold feet. She has experienced many episodes of bronchitis, although her respiratory health improved markedly after her spinal fusion. Unusually, she recently developed inflammatory bowel disease. There are many limitations to her health and functioning, but she also lives a full life. She loves larking around with her family -her big eyes light up -and she enjoys school, music and swimming.
Written consent for publication of this case report was obtained from a responsible relative.
for epidemiological research 104 . Subsequently, it was recommended that cases not fulfilling all the necessary criteria should be designated as atypical 105 . In Europe, the term 'variant' was used to describe a range of Rettlike phenotypes that were categorized as atypical in other regions. These phenotypes included forme fruste (BOX 2; see Supplementary information S2 (video)), congenital, infantile seizure onset 106 , male, late childhood regression and preserved speech variants 107 . Subsequently, a model to categorize atypical RTT in "a girl with unspecified mental retardation, aged 10 years or more" was developed, and required the presence of three or more primary criteria and five or more supportive criteria 108 At a meeting in Baden-Baden in 2001, the existing three sets of criteria 4, 5, 108 were assessed and combined to form two new versions, one for classic RTT (BOX 1; see Supplementary information S1 (video)) and one recognizing atypical RTT (BOX 2; see Supplementary information S2 (video)) as its own entity 6 (FIG. 1) . The new criteria reflected some additional lessons that had been learned since the formulation of the previous criteria, such as the fact that early development was not invariably normal 109 , and that head growth did not always decelerate 110 . In 2010, a further set of criteria was introduced in the hope of clarifying some of the differences in terminology between Europe and North America 7 (FIG. 1) . In contrast to previous iterations, and in addition to the four core criteria relating to loss of hand skills, loss of spoken language, gait abnormality and stereotypic hand movements, a mandatory criterion of a period of regression followed by recovery or stabilization was introduced. For atypical RTT, a period of regression was also mandatory, but only two of the four criteria were required, along with at least five of eleven supportive criteria. One may question the need for the additional regression criterion, given that regression in some patients is often described as "fleeting or unrecognized 111 ," or may not yet have occurred at the time of genetic testing, which is now widely used by clinicians diagnosing RTT. Although dependence on clinical criteria without genetic confirmation is necessary in some parts of the world, in many developed countries direct sequencing is being replaced by a range of next-generation sequencing techniques, including targeted gene sequencing, whole-exome sequencing and whole-genome sequencing. Consequently, molecular testing for children with developmental problems could be undertaken at an early age before the hallmark features that characterize particular disorders have become apparent. These technological advances may eventually prove to be more efficient and cost-effective for diagnosis 112 , and the RTT clinical criteria that relate to the evolution of the disorder could become redundant.
The final component of the most recent criteria 6 provides further clinical description of some of the original 'variant' forms, two of which -the early seizure onset variant now recognized as the CDKL5 disorder 113 and the congenital variant, mostly caused by mutations in FOXG1 (REF. 114 ) -must now be considered only as Rett-related disorders 111 . The third atypical form, the Zappella or preserved speech variant 107 , is most often associated with an Arg133Cys mutation 115 or a C-terminal deletion 116 (FIG. 2) . However, by additionally describing the forme fruste, late regression and male variants, Hagberg had already provided the best delineation of the full spectrum of clinical presentations 117 . As we reflect today on these early descriptors, we can see how well they fit with our current understanding of the relationships between genotype and phenotype.
Overall severity and relationship with genotype. As early as 1987, the issue of the danger of masking the true clinical variation in RTT (BOXES 1,2; see Supplementary information S1,S2 (videos)) by the adoption of 'artificial' inclusion and exclusion criteria based on phenotype and not on cause was raised by the esteemed medical geneticist John Opitz 118 . Much later, and endorsing this concept in a different way, Hagberg acknowledged the wide clinical variation of what he called the "MECP2-deviant phenotypes, " with a spectrum ranging from the severe newborn encephalopathy in males to the female carrier mothers 119 . We now know, as Opitz might have predicted, that much of this spectrum relates to the type of genetic mutation, with the very mild variants often represented by individuals with C-terminal deletions in MECP2 
see Supplementary information S2 (video)). Although RTT is mostly considered
Box 2 | Mild Rett syndrome phenotype
The mild Rett syndrome (RTT) phenotype is exemplified by a 13-year-old girl with a Pro389X mutation in the methyl-CpG-binding protein 2 (MECP2) gene (see Supplementary information S2 (video)). This teenage girl illustrates the mild phenotype of a C-terminal deletion, possibly further influenced by another genetic modifier.
Initially, the girl progressed well, learning to walk at 12 months, and feeding herself and using four-word sentences as a toddler. However, speech delay, poor sleep and tremulous movements, which developed when she was 2 years old, raised some concerns. The girl's mother began to suspect RTT when her daughter was 4 years old. After the girl developed epilepsy at 8 years of age, the possibility of RTT was dismissed because of her high level of gross motor skills (walking well across different terrains), good hand use and ability to maintain a conversation. In addition, her head growth had not decelerated. Her mother's continued concern led to further genetic testing at 12 years, which demonstrated a MECP2 C-terminal deletion (Pro389X). The lateness of diagnosis was consistent with her mild clinical presentation .
In retrospect, the girl experienced loss of finesse in her ability to turn pages when she was 2-3 years old, but showed no loss of communication skills. Her gait is mildly ataxic and she developed mild hand stereotypies at 6 years of age. She has had ongoing sleep disturbances since 3 years, her feet are cold and small, she has decreased sensitivity to pain, and displays substantial tremor, which is managed with trihexyphenidyl and a vagal nerve stimulator. Consistent with the C-terminal phenotype, her growth is good. A diagnosis for this young girl has provided important answers to her family.
Beyond RTT, the girl is deeply involved in family, school and community life. She loves fun times with her father and competes in the Special Olympics in horse riding. Her diagnosis is an important part of her life, but is also compatible with learning and participation.
Written consent for publication of this case report was obtained from a responsible relative. . " The Australian register first provided the means to examine the spectrum of presentations in a total RTT population cohort using three previously published measures, designated as the Kerr 122 , Percy 123 and Pineda 124 scores 125 . Considerable variability in the early regression period, current functioning and comorbidities, much of which was subsequently shown to relate to genotype, was demonstrated, and severity generally increased with age.
Despite numerous small studies, it took time to accumulate adequate data to provide consistency in genotype-phenotype relationships. The two most seminal studies were published within months, the first using data from InterRett 126 , and the second from the US Natural History study 127 . Where comparable, the findings were broadly similar, with the most severe mutations being Arg270X, Arg255X and Arg168X, whereas Arg133Cys, Arg294X and C-terminal deletions produced less-severe phenotypes (BOXES 1,2; FIGS 2,3a; see Supplementary information S1,S2 (videos)). Overall, individuals with severe mutations were less likely to walk, retain hand use or use words, and tended to be diagnosed at an earlier age 128 (FIGS 2,3b,4). A group with large deletions, which was not included in the initial InterRett study, was subsequently described separately, thereby confirming earlier US findings 127 of phenotypic severity 129 (FIGS 2,3a). A later publication also studied the C-terminal deletions -a milder group which, due to their comparatively later loss of skills and onset of stereotypies 120 , fitted with the initial 'late regression' descriptor (BOX 2; FIGS 2,3a; see Supplementary information S2 (video)). Also of interest were the better growth parameters and increased likelihood of kyphosis in individuals with C-terminal deletions 120 . Information from these 120, 126, 127, 129 and other studies 20 is enormously useful when considering prognosis in RTT, although it is clear that genotype is but one factor, and other factors, such as X-inactivation 130 , genetic modifiers 131 and, possibly, environmental factors 132 , also have a role (BOX 2; see Supplementary information S2 (video)).
Variation in functional abilities. The classic signs of RTT include severe functional impairments, usually necessitating substantial support in daily life. Subtle changes in development often precede the onset of regression 109 , which is characterized by either gradual or sudden loss of hand and communication skills, loss of balance, and development of hand steretoypies 7, 133 . Patterns in the relationships between genotype and hand and gross motor skills have been observed 126, 134, 135 . Although cross-sectional studies suggest that motor function declines with increasing age, further longitudinal research is necessary to confirm or refute this idea. For example, some adults with RTT -probably those with a mutation associated with a milder phenotyperetain the capacity to walk 136, 137 (FIGS 2,4a). Similarly for communication, those with milder mutations such as Arg133Cys or Arg306Cys are more likely to learn to babble or use words before regression, to regress at a later age, to retain some oral communication skills after regression, and to be diagnosed later 115, 128 (FIGS 2,3b,4c ).
For individuals with RTT, a fundamental goal is to build the capacity for movement and communication in everyday life, and with a deeper understanding of motor deficits, the potential role of the enriched environment 132 , and technological advances in assisted communication systems, the capacity to respond C a n m a n i p u l a t e C a n g r a s p L o s t a l l N e v e r h a d C a n m a n i p u l a t e C a n g r a s p L o s t a l l N e v e r h a d C a n m a n i p u l a t e C a n g r a s p L o s t a l l N e v e r h a d C a n m a n i p u l a t e is expanding. However, no relevant studies, beyond single or small case series 138, 139 , have been conducted, so we do not fully understand what interventions are associated with favourable outcomes, and how treatments should be modified for variation in phenotype.
Comorbidities and their management
Epilepsy. Epilepsy is a particularly challenging comorbidity to study in RTT. Although the EEG is uniformly abnormal, typically from about 18 months of age 140 , this finding does not necessarily reflect seizure activity 141 . Moreover, some seizures seen during video-EEG monitoring may not be recognized by caregivers as clinical events, and many events characterized by caregivers as seizures are not associated with EEG seizure discharges. These issues have contributed to difficulties in validating an epilepsy diagnosis and recording the seizure history for research, and probably to the comparative dearth of literature.
With these caveats in mind, a number of investigations have been undertaken to study epilepsy in RTT. Epilepsy was diagnosed in 95% of a Swedish representative series (n = 53), although seizure frequency declined with age 142 . In one Australian study, the prevalence of epilepsy diagnosis was 81%, with a median age of onset of 4 years 143 . In another study, seizure rates were found to be generally higher in individuals with greater clinical severity and lower in those with Arg294X or Arg255X mutations or C-terminal deletions 144 . In recent years, three substantially sized studies have reported on epilepsy in RTT [145] [146] [147] . On average, just over 60% of cases were diagnosed with epilepsy, but in a US study 145 , a lower proportion had physician-verified seizures. Variations that were observed in relation to the effects of genotype (FIGS 2,5a) may have resulted from methodological differences, but in all three studies the mutation Thr158Met conferred some additional risk of epilepsy [145] [146] [147] . Growth and nutrition. Growth retardation was listed in the early versions of the supportive criteria for RTT 5 , with head growth deceleration occurring first, followed later by slowing of weight and height increase, and even of hand and foot growth 148 . Although the exact underlying mechanism remains unclear [149] [150] [151] , a definite relationship with genotype exists 120, 150 . Growth charts have been generated using cross-sectional and longitudinal data from 816 US cases, and the growth failure was found to be especially pronounced in individuals with the more severe Thr158Met, Arg168X, Arg255X, Arg270X and large deletion mutations 152 (FIGS 2,3a) . Enteral support for individuals with RTT is common practice in developed countries. This approach is now being used in over one-quarter of cases 153 , particularly those with large deletions and Arg168X mutations (FIG. 2) , with apparent benefits in terms of both growth parameters and parental satisfaction 153 . A large multinational group collated existing evidence and used expert opinion to provide guidance on the assessment and management of growth and feeding problems in RTT 154 . These published guidelines, which are available in userfriendly formats for clinicians and families, represent an important step in tackling this comorbidity 154 .
Autonomic dysfunction. Individuals with RTT commonly exhibit abnormal breathing patterns, which are considered to be a manifestation of autonomic dysregulation. These problems generally present as episodes of either hyperventilation or breath-holding 155, 156 . Abdominal bloating, which in rare cases can lead to gastric perforation 157 , is a common sequela, and may need alleviation through the release of air via a gastrostomy. Vasomotor disturbances causing cold and blue hands and feet were also identified as supportive clinical criteria for RTT 5 . Despite the intensive autonomic monitoring that is now undertaken in some European centres 155 , the prevalence and natural history of these disturbances, and their potential relationships with genotype, remain unknown. The literature on autonomic disturbance in humans with RTT is currently lagging behind that in animal models 158 . This knowledge gap is worrying, given that animal studies suggest the need for pharmacological interventions, and clinical trials of compounds that aim to reduce autonomic dysfunction are imminent.
Scoliosis.
With the combination of neurological impairment and altered motor skills in individuals with RTT, the development of deformity such as scoliosis can be relentless. An early case series indicated that neurological signs were often asymmetrical, with the right side being more severely affected 159 , and subsequent larger studies found scoliosis to be a common deformity 160, 161 . In the Australian study, 75% of girls developed scoliosis by 15 years of age, with earlier onset in those with more severe mutations, such as Arg255X or large deletions 160 (FIGS 2,5b). Scoliosis is usually progressive, particularly in children who are unable to walk, and in those with b | Incidence of scoliosis diagnosis by MECP2 mutation type in 392 individuals with RTT. Data points are the mean incidence, with 95% confidence intervals 160 . c | Relationship between sleep disturbances (disorders of initiating and maintaining sleep, or DIMS) and MECP2 mutation type in 325 individuals with RTT. Data points are the mean DIMS score adjusted for age, seizure frequency and mobility, with 95% confidence intervals 168 . ◀ most common mutations other than Arg306Cys 160 . The health implications can be profound, as scoliosis with a Cobb angle >70° has particularly detrimental effects on respiratory health 162 . In response to a poor evidence base, an international group developed a set of clinical guidelines for the management of scoliosis in individuals with RTT, using the available literature but also drawing heavily on the literature for neuromuscular scoliosis. The consensus was that scoliosis should be regularly monitored and spinal fusion considered when the Cobb angle is >50° (REF. 163 ). In a subsequent study, spinal fusion was associated with improved survival and, in individuals with early-onset scoliosis, a moderate reduction in frequency of severe respiratory tract infections 164 . This information is important for clinicians and families when weighing up the pros and cons of spinal fusion in individual girls and circumstances 165 .
Sleep disturbances. Sleep disturbances have recently been considered as supportive criteria for RTT 6, 7 , and their burden on the affected person and their family is often considerable. An early Australian study in individuals with RTT (n = 83) reported poor night time sleep overall, and daytime naps that persisted with age 166 . Seizure disorders were associated with increased daytime sleep, and ability to walk was associated with less daytime sleep 166 . Further population-based research found a high prevalence of sleep problems, some of which (in particular, night laughing and screaming) decreased with age 167, 168 . The highest likelihood of sleep problems was observed in individuals with a large deletion -in whom night laughing was particularly common -or with Arg294X 167, 168 (FIG. 2) .
A recent study, which used InterRett for ascertainment, surveyed parents or carers of 364 genetically confirmed cases aged 2-57 years 169 . Night waking was frequent and, consistent with previous research, individuals with the Arg294X mutation were most likely to have problems initiating and maintaining sleep 169 (FIGS 2,5c).
Individuals with epilepsy and/or limited mobility were more likely to have excessive somnolence, also consistent with earlier findings 166 . In one small clinical trial (n = 9), melatonin seemed to improve total sleep time and efficiency in individuals with poor sleep quality at baseline, without any adverse effects 170 . Considering the frequency of sleep dysfunction in RTT, and its impact on the child and their family, our evidence base for management remains remarkably sparse.
Bone health. Unlike other comorbidities, adverse bone health has not been one of the supportive criteria for RTT. Susceptibility to osteopenia and fractures was first highlighted through US 171 and Australian research 172, 173 . Fracture risk was four times higher in individuals with RTT than in the general female population, and was specifically increased in those with Arg168X and Arg270X mutations 173 (FIG. 2) . 174, 175 , US 176, 177 and Australian studies 178, 179 have investigated which particular bone parameters are most adversely affected in RTT, and their potential nutritional 180 (for example, vitamin D status), environmental and genetic risk factors. Risk factors for fractures, such as genotype 173 and use of certain antiepileptic medications 181 , did not always correlate exactly with those for low bone density, which also varied by outcome parameter and body site. For example, in comparison with other parameters, right femoral neck areal bone mineral density was particularly impaired with increasing age and lack of mobility 178 . A recent Danish study concluded that comparatively reduced levels of biochemical bone markers in RTT signified a low bone turnover state 182 . Cross-study comparison has been hindered by non-representative and small sample sizes, often without longitudinal collection, as well as a lack of childhood population bone parameter norms and accommodation for decreased stature and different analytical methods.
Several Danish
MeCP2 deficiency has been shown to alter the biomechanical integrity of bone in a mouse model 58, 59 , underlining the importance of understanding bone health in RTT. A set of guidelines for bone health was developed, which aimed to provide the best available evidence at the time of publication 183 . We hope that these guidelines can soon be modified with results from clinical trials assessing the effectiveness of drugs such as bisphosphonates in RTT 184 .
Therapeutic strategies
The increased understanding of MeCP2 function and the availability of valid cellular and animal models has fuelled efforts to identify and develop therapeutic strategies for RTT [185] [186] [187] [188] . These efforts include targeting of the various brain systems and downstream cellular processes that are affected in RTT, as well as approaches that target the root cause of the disorder, namely, MeCP2 dysfunction 185 (FIG. 6) .
Approaches that target MeCP2 at the level of the gene or protein to restore functional MeCP2 within the nervous system are appealing, as they have the potential to produce profound amelioration or reversal of symptoms, as demonstrated by reversal studies in mice 43, 44, 189 . Such approaches involve molecular and genetic manipulations, ranging from gene transfer 190, 191 and protein substitution to novel forms of DNA and RNA editing 192 . However, the level of MeCP2 in a given cell may be critical 193 , and restoring MeCP2 function without producing overexpression-related pathology is likely to be a considerable challenge. Strategies targeting MECP2 typically require the development of completely novel molecules, which creates substantial uncertainty in terms of adequate brain delivery, safety and ensuing regulatory hurdles. The MeCP2 protein is a macromolecule with multiple functional domains, and restoration of normal function using small-molecule drugs is not considered to be practical. However, it might be possible to develop small molecules to act at the genomic level to reactivate the MECP2 allele on the inactive X chromosome 194 , or at the level of RNA to enable read-through of nonsense mutations 195, 196 . In contrast to targeting of MECP2, pharmacological strategies that target downstream mechanisms in the pathogenic process can make use of small molecules that (FIG. 6) . However, such approaches do not address the underlying aetiology, and the lack of a dominant cellular process or pathway downstream of MeCP2 deficiency suggests that the benefits could be restricted to a subset of symptoms. The approaches that have been developed to date can be broadly divided into three categories: pharmacological agents that affect major neurotransmitter systems in the brain, most notably glutamate, GABA, acetylcholine and monoamines (FIG. 6) ; drugs and trophic factors that promote brain growth and development, mostly by modulating the brain-derived neurotrophic factor pathway; and drugs that modulate other cellular processes known to be perturbed in models of RTT, such as energy metabolism and protein synthesis.
Clinical trial design
Clinical trials for rare disorders present many challenges, including mutation heterogeneity, variation in disease severity, and the pool of available participants. Additional considerations include the optimal time for intervention and the nature of trial design 185 . Important starting points include high-quality natural history data, and objective and robust outcome measures. Several clinical severity scores 122, 124, 197 have worked well in studies of genotype-phenotype relationships 126,127 , but have not necessarily proved to be optimal as outcome measures in clinical trials 198 .
For example, the Motor-Behavioural Assessment (MBA), which comprises 39 items scored with a five-point scale to describe clinical severity 199 , was used in one clinical trial 198 . However, this scale is poorly operationalized, with some items describing historical aspects of regression, and has never been validated. Similarly, the Rett Syndrome Behaviour Questionnaire 200 was developed for the purpose of differentiating individuals with RTT from those with other causes of intellectual disability before genetic testing became available. This questionnaire has been used successfully in genotype-phenotype studies to assess some aspects of behaviour such as mood and anxiety 137, 201 , but may not appropriately measure behaviour as an outcome in a clinical trial. A clear need exists for the further development of such instruments, and work is currently underway in this regard 202 . The Clinical Global Impression scales are clinicianrated, seven-point rating scales that are used to describe severity and change, and have recently been adapted to RTT for use in clinical trials 203 . This process has involved the development of seven category descriptors for the domains of communication, ambulation, hand use, use of eye contact, autonomic function, seizures, and attentiveness. Initial validation studies, including testing of responsiveness to change, are being undertaken 203 . More sensitive measures of specific domains are also becoming available. For example, the 15-item Rett Syndrome Gross Motor Scale has undergone substantial validation, suggesting capacity to demonstrate responses to interventions in the motor domain 135 . Wearable technologies have also been used for objective measurement of the patterns and regularity of respiratory and cardiac function in RTT in small observational studies 156, 204 , and in a recent clinical trial 198 . Thus, some progress is being made in the important area of outcome measures, but much work is still needed to ensure that future clinical trials are able to provide the necessary answers.
Global efforts to study a rare disorder Epidemiology. The Texas registry, which used multiple sources of ascertainment monitored with capturerecapture methods, was the first population-based registry to be established for RTT 205 . This registry provided a model for the Australian Rett Syndrome Database (FIG. 1) , which in 1997 reported that RTT had a cumulative incidence of 0.96 per 10,000 females by the age of 12 years 206 . Further studies in 2011 demonstrated that the cumulative incidence was increasing with age, and that the median age at diagnosis had fallen from 4.5 years before 1999 to 3.5 years after this date 207 .
Infrastructures. The establishment of registries is a first step towards understanding the epidemiology, natural history and life expectancy of a rare disorder. Following Alison Kerr's use of the British Paediatric Surveillance Unit to launch the British Isles RTT Survey in 1990 (REF. 208 ), the Australian database (FIG. 1) , established 3 years later, took advantage of the newly formed Australian Paediatric Surveillance Unit to ascertain cases 206 . The database has now been maintained for over two decades, and each additional year of follow-up increases its value 137 , providing the capacity to monitor children into adulthood and identify trajectories of functioning and comorbidities 209 . Population-based longitudinal follow-up with minimization of attrition is essential for studies of life expectancy, but is uncommon in the field of rare disorders.
Genotype-phenotype investigations are, ideally, sourced from population-based sources 210 , but when mutations are rare or effect sizes are small, large sample sizes, sometimes obtained through aggregation of data from multiple sources, can provide much greater power. InterRett is one infrastructure that has served this purpose well by collecting questionnaire data internationally from both clinicians and families in over 50 countries since 2003 (REF. 211) (FIG. 1) . Another such infrastructure, but based solely in the US, is the Rare Disease Consortium Research Network for RTT 145 , which was initially established in 2004 by Alan Percy as a natural history study 212 (FIG. 1) , and is now funded by the NIH. Although both of these data collections are likely by their nature to be highly selective, it has been possible to compare some characteristics of InterRett with an Australian population-based source 213 . The InterRett families were of a somewhat higher socioeconomic status than the Australian families, but the distributions of mutation type were broadly comparable.
The original structure of the NIH-funded study involved the collection of data from clinic visits to inform the understanding of the natural history of RTT. Currently, the main aim is to increase our knowledge of the molecular basis of RTT, and to identify treatments that could improve functioning in affected individuals. Like InterRett, the European Rett Syndrome Database Network (EuroRett) combines data from multiple sources, and to date has mainly been applied to investigations on epilepsy 147 . RettBASE, the MECP2 Variation Database, has a different but valuable function, which is to catalogue the range of different genetic variants, both pathogenic and non-pathogenic, reported in publications and from laboratories 214 .
Role of advocacy groups. Advocacy groups have played a major part in the funding of infrastructures and RTT research. The main organization, which provides support and advocacy as well as funding, was established in 1984 as the International Rett Syndrome Association (IRSA) 215 . When commenting about the achievements of this organization, its founder, Kathy Hunter, wrote that "parents soon understood the critical part they must play in making sure that funds are available for research" and "they also understand the need for them to participate vigorously in research 216 . "
International collaboration -challenges and accomplishments. International collaborations are vital for rare disease research. Over the years, however, differences have emerged at the international level in the understanding of RTT, and particularly in its associated terminology. Such differences can hamper progress. One example is a simple scoring system initially proposed by a UK researcher, which has not been widely adopted in North America 122 . Another is the wide variation in autonomic monitoring and management, which is underpinned by limited evidence 155 . The Australian group has led a number of successful collaborative initiatives to develop guidelines for treatment of common RTT comorbidities. Often, in the absence of a strong evidence base, these initiatives depended on expert opinion garnered in a collegial fashion through the Delphi process 154, 163, 183 .
Conclusions and future prospects
In terms of the clinical presentation, many components of the original model of RTT proposed by Hagberg still ring true. Over the past 50 years, life expectancy for individuals with RTT has increased dramatically, partly because of changing attitudes and allocation of resources towards the health care of those with disability.
The value of surgical treatment for scoliosis was first highlighted by Kerr et al., who reported positively on family perspectives of well-being 1 year after the fusion operation 217 . The benefits of this approach were further validated in recent studies, which used population-based data 164, 218 . Enteral nutrition is now commonly available, at least in developed countries, and preliminary evidence indicates a positive impact on growth 153 . The beneficial effects of these management approaches may be reflected in the 71% survival rate at 25 years, reported in an Australian population cohort in 2010 (REF. 219 ), compared with 21% in Rett's original cohort. Recent population data, using longitudinal follow-up over more than two decades, suggest that approximately 60% of individuals with RTT will survive to their late thirties 137 . This figure is considerably less optimistic than the estimates of 50% at 50 years from the North American Database 220 (data derived from 50% response to questionnaires administered to IRSA family members) and 75% at 45 years from a 9-year follow-up of the US Natural History sample 221 . Both of the latter samples are large but select groups, and are likely to be more economically advantaged than the general US population.
Other societal changes include our passage into the digital age: the value of connecting families affected by RTT via the Internet was first demonstrated only 12 years ago 222 . Nowadays, social media sites are often the first port of call for families with a new diagnosis. Traditionally wary of patients seeking information from non-reputable sources, clinicians now appreciate the importance of this virtual peer support, especially for geographically isolated families affected by a rare disease.
The greatest explosion of knowledge on RTT has occurred in the 16 years since the discovery of the genetic cause. During this period, US and Australian natural history studies and international databases have informed our understanding of genotype-phenotype relationships, and the comorbidities that occur in this disorder. We have learned much about the function of the MeCP2 protein, in particular, its role as a regulator of gene expression and its interaction with other proteins. The reversal of neurological deficits in a mouse model in 2007 (REF. 43 ) raised hopes of a treatment that can restore MeCP2 expression in humans.
Although some progress has been made in improving clinical management, we still lack treatment options to resolve or substantially reduce the comorbidities of RTT. Many individuals -as well as their families -are adversely affected by poor sleep, a substantial proportion have refractory epilepsy, no evidence-based management options are available for autonomic breathing abnormalities, and the best methods to improve functional ability are not yet known. These are all important clinical challenges to address.
The probability of translating promising preclinical outcomes to effective clinical treatments for nervous system disorders is modest, and expectations must be tempered accordingly. However, the developing pipeline of putative therapies, and the coordinated efforts of clinicians, scientists and family organizations, together with increasing engagement of the biomedical industry, assure exciting developments ahead.
